KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Change in Accured Expenses: 2020-2025

Historic Change in Accured Expenses for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to -$8.0 million.

  • Recursion Pharmaceuticals' Change in Accured Expenses fell 226.52% to -$8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.7 million, marking a year-over-year decrease of 473.76%. This contributed to the annual value of $5.5 million for FY2024, which is 17.86% down from last year.
  • According to the latest figures from Q3 2025, Recursion Pharmaceuticals' Change in Accured Expenses is -$8.0 million, which was down 170.60% from $11.4 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' 5-year Change in Accured Expenses high stood at $12.2 million for Q4 2022, and its period low was -$26.6 million during Q1 2025.
  • Its 3-year average for Change in Accured Expenses is -$1.0 million, with a median of $6.2 million in 2023.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Change in Accured Expenses skyrocketed by 1,156.33% in 2021, and later plummeted by 11,680.00% in 2022.
  • Over the past 5 years, Recursion Pharmaceuticals' Change in Accured Expenses (Quarterly) stood at $1.6 million in 2021, then soared by 641.26% to $12.2 million in 2022, then slumped by 77.12% to $2.8 million in 2023, then surged by 278.01% to $10.5 million in 2024, then slumped by 226.52% to -$8.0 million in 2025.
  • Its Change in Accured Expenses was -$8.0 million in Q3 2025, compared to $11.4 million in Q2 2025 and -$26.6 million in Q1 2025.